TYMS and neoplasm: A number of clinical studies have illustrated that pretreatment levels of folate and homocysteine are predictive for both tumour response and toxicty in patients treated with either thymidylate synthase (TS) inhibitors or folate antagonists (Bunn et al, 2001; Calvert, 2002; Niyikiza et al, 2002).